Sunday 18 October 2026
Export ABVC’s income statement to Excel — free account
ABVC BioPharma, Inc.
ABVC Healthcare Biotechnology
ABVC BioPharma, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $509,600.00, up 234.4% from fiscal 2023. In the quarter to June 2026, revenue grew 66,233.3%, EPS grew 76.9% and free cash flow grew 72.7%, each against the same quarter a year earlier.
0.92
0.01
−1.08%
Follow ABVC
| Sep '17 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 2 | 5 | 3 | 3 | 6 | — |
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/S ratio |
— | — | 63,310.91 | 108.98 | 208.14 | 238.71 | 19.59 | 34.12 | 13.52 | — |
Altman Z-Score |
— | — | 15.70 | 0.73 | 1.41 | 4.23 | (11.58) | (14.59) | (14.88) | — |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
— | — | (21.86) | (16.45) | (11.06) | (10.95) | (30.50) | (36.21) | (37.70) | — |
Beneish M-Score |
— | — | — | 70.57 | (5.31) | (3.14) | (5.43) | — | (3.98) | — |
P/Operating CF |
— | — | 1,560.31 | (51.12) | (45.96) | (33.64) | (41.20) | (12.09) | (9.81) | — |
P/B ratio |
— | — | 0.00 | 0.00 | 37.77 | 9.58 | 5.87 | 4.15 | 9.51 | — |
Price to Tangible BV |
— | — | 0.00 | 0.00 | 38.71 | 9.65 | 5.99 | 4.38 | 10.45 | — |
EV/Sales |
— | — | 63,320.35 | 109.75 | 208.79 | 226.39 | 21.88 | 51.06 | 15.10 | — |
EV/EBITDA |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
— | — | (464.09) | (24.57) | (22.10) | (10.60) | (2.87) | (1.86) | (4.25) | — |
EV/FCF |
— | — | (464.09) | (24.57) | (22.10) | (10.58) | (2.82) | (1.85) | (4.19) | — |
Quick Ratio |
78.94 | 0.60 | 0.03 | 0.07 | 1.10 | 1.92 | 0.42 | 0.26 | 0.32 | 0.23 |
Current Ratio |
78.94 | 0.60 | 0.05 | 0.13 | 1.27 | 2.07 | 0.54 | 0.27 | 0.33 | 0.41 |
Net Debt/EBITDA |
0.05 | (0.25) | (0.02) | (0.03) | 0.28 | 0.57 | 0.10 | 0.12 | 0.21 | 0.21 |
Debt/Assets |
0.00% | 41.99% | 5.14% | 3.59% | 22.61% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | (0.63) | (0.06) | (2.00) | 0.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.11 | 0.05 | 0.03 | 0.08 | 0.02 | 0.07 | 0.00 |
Operating CF/Net income |
0.39 | 0.35 | 0.16 | 0.86 | 0.47 | 0.59 | 0.45 | 0.54 | 0.37 | 0.38 |
Capex/Depreciation |
— | — | 0.00 | 0.00 | 0.00 | (1.46) | (5.03) | (0.06) | 0.00 | 0.00 |
Interest Coverage |
(53.28) | (39.99) | (6.02) | (7.18) | (21.00) | (51.52) | (51.41) | (5.15) | (5.70) | (17.19) |
| 104.78% | 269.39% | 157.11% | 133.27% | (771.78%) | (222.66%) | (271.31%) | (346.94%) | (495.87%) | (112.81%) | |
| (277.73%) | (157.20%) | (129.91%) | (56.60%) | (105.65%) | (101.47%) | (141.11%) | (89.70%) | (63.99%) | (55.30%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (1,864.65%) | (333.03%) | (534.12%) | (924.61%) | 0.00% | (37.54%) |
Return on Tangible Assets |
(149.71%) | 241.50% | 56.25% | 67.25% | (531.15%) | (286.11%) | 828.45% | 200.94% | 126.80% | (86.22%) |
Average Days of Receivables |
0.00 | 0.00 | 2,033.57 | 159.59 | 229.05 | 437.12 | 322.06 | 1,819.25 | 827.34 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 14,124.29% | 149.44% | 113.81% | 282.12% | 277.74% | 697.44% | 35.18% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 23,107.14% | 440.62% | 1,743.35% | 3,106.49% | 1,351.24% | 3,644.49% | 987.99% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 411.43% | 3.18% | 858.59% | 1,491.51% | 725.59% | 121.98% | 544.25% | 0.00% |
Graham Net Nets |
— | — | (0.03) | (0.08) | (0.03) | 0.03 | (0.18) | (0.94) | (0.67) | — |
Graham Number |
— | — | 23.70 | 1.87 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
— | — | (1.51%) | (5.00%) | (9.58%) | (15.01%) | (86.67%) | (204.17%) | (66.10%) | — |
Free Cash Flow Yield |
— | — | (0.22%) | (4.10%) | (4.54%) | (8.97%) | (39.57%) | (80.96%) | (26.64%) | — |
Revenue per Share |
0.00 | 0.00 | 0.01 | 0.40 | 0.25 | 0.14 | 0.31 | 0.04 | 0.04 | 0.00 |
Operating CF per Share |
(1.35) | (1.25) | (0.78) | (1.79) | (2.31) | (3.03) | (2.34) | (0.97) | (0.15) | (0.15) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | (0.04) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(1.35) | (1.25) | (0.78) | (1.79) | (2.31) | (3.04) | (2.37) | (0.97) | (0.15) | (0.15) |
Cash per Share |
0.17 | 0.08 | 0.21 | 0.09 | 2.54 | 2.66 | 0.46 | 0.18 | 0.08 | 0.07 |
Shareholders Equity per Share |
(1.18) | (1.48) | (4.60) | (0.07) | 1.35 | 3.54 | 1.02 | 0.29 | 0.06 | 0.66 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(1.18) | (1.48) | (4.60) | (0.07) | 1.35 | 3.54 | 1.02 | 0.29 | 0.06 | 0.66 |
Free Cash Flow |
(1.60) | (1.49) | (0.90) | (3.13) | (4.56) | (7.62) | (7.52) | (4.21) | (1.81) | (2.99) |
Working Capital |
2.72 | (1.76) | (10.42) | (5.94) | 1.33 | 3.96 | (2.56) | (4.45) | (4.38) | (3.66) |
Capital Expenditures |
— | — | — | — | — | (0.02) | (0.12) | (0.02) | — | — |
Net Current Asset Value |
(1.39) | (1.76) | (10.71) | (6.17) | (2.77) | 2.83 | (3.36) | (4.87) | (4.64) | (5.26) |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.05 | 0.12 | 0.14 | 0.00 | — |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
— | — | 0.09 | 0.11 | 0.07 | 0.02 | 0.04 | 0.67 | 0.39 | 0.04 |
Cash ROIC |
134.55% | 268.30% | 18.79% | (1,101.37%) | (44.36%) | (48.99%) | (159.84%) | (205.31%) | (109.47%) | (20.33%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.01 | 4.06 | 1.58 | 0.98 | 1.51 | 0.19 | 0.53 | — |
Accounts Payable Turnover |
— | — | 0.00 | 0.95 | 0.80 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | 176.48 | 0.00 | 28.77 | 0.39 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
— | — | 0.00 | 435.82 | 448.93 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | 2.56 | 0.00 | 0.00 | 1,860.78 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
1.28 | 2.55 | 1.29 | 0.17 | 0.30 | 0.36 | 0.64 | 0.81 | 0.96 | — |
Average Payables |
— | — | — | 0.02 | 0.02 | — | — | — | — | — |
Average Inventory |
— | — | 0.00 | — | 0.00 | 0.01 | — | — | — | — |
Average Assets |
1.47 | 2.70 | 4.29 | 6.43 | 9.27 | 12.65 | 11.64 | 8.68 | 7.66 | 14.30 |
Average Common Equity |
(3.89) | (1.57) | (3.55) | (2.73) | 1.27 | 5.77 | 6.05 | 2.24 | 0.99 | 7.01 |
Columns are period end dates · fundamentals updated 28 Sep 2026